This study compared the in vitro activity of telithromycin, the first ketolide developed for clinical use, with that of azithromycin, one of the most commonly used macrolide for treatment of respiratory tract infections, against 198 Streptococcus pneumoniae isolates at some North West Italy’s hospitals between 2005-2007. Erythromycin-resistance phenotypes were determined to correlate the different bacterial resistant pattern to antimicrobial susceptibility. The uniform activity of telithromycin against S. pneumoniae, including Ery-R isolates, suggests that this ketolide may offer a valuable alternative for treatment of streptococcal infections. Furthermore, in addition to several other reports, even the findings from this regional study, emphasize that an active surveillance of phenotype distribution and antibacterial resistance in pneumococci is essential to guide the effective use of empirical treatment option for streptococcal infections

Regional trends in telithromycin and azithromycin resistance among Streptococcus pneumoniae isolates

ALLIZOND, VALERIA;BANCHE, Giuliana;ROANA, Janira;MANDRAS, Narcisa;SCALAS, Daniela;TULLIO, Viviana Cristina;CARLONE, Nicola;SAVOIA, Dianella;CUFFINI, Annamaria
2008

Abstract

This study compared the in vitro activity of telithromycin, the first ketolide developed for clinical use, with that of azithromycin, one of the most commonly used macrolide for treatment of respiratory tract infections, against 198 Streptococcus pneumoniae isolates at some North West Italy’s hospitals between 2005-2007. Erythromycin-resistance phenotypes were determined to correlate the different bacterial resistant pattern to antimicrobial susceptibility. The uniform activity of telithromycin against S. pneumoniae, including Ery-R isolates, suggests that this ketolide may offer a valuable alternative for treatment of streptococcal infections. Furthermore, in addition to several other reports, even the findings from this regional study, emphasize that an active surveillance of phenotype distribution and antibacterial resistance in pneumococci is essential to guide the effective use of empirical treatment option for streptococcal infections
18th European Congress of Clinical Microbiology and Infectious Diseases
Barcellona
19-22 april 2008
Abstracts of the 18th ECCMID
ESCMID
14 (s7)
s145
s146
streptococci; macrolide-resistance; resistant phenotypes
V. Allizond; G. Banche; J. Roana; N. LI Vigni; N. Mandras; D. Scalas; V. Tullio; N. Carlone; D. Savoia; A. Barbui; A Cuffini
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/67333
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact